Clary Clish is the Director of Metabolite Profiling at the Broad Institute of MIT and Harvard. His lab is expert in the development and application of liquid chromatography tandem mass spectrometry-based metabolomics techniques. His group has contributed a number of discoveries of metabolic indicators of future disease, including type 2 diabetes and pancreatic cancer, in population based cohorts. He received his B.Sc. in Chemistry & Biological Sciences from McGill University in 1991 and his Ph.D. from Portland State University in 1996. From 1997-2001, Dr. Clish was a postdoctoral fellow and junior faculty member in the laboratory of Dr. Charles Serhan at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham & Women’s Hospital and Harvard Medical School where he co-discovered the class of lipid mediators now termed “resolvins.” Prior to joining the Broad Institute in 2008, he was Vice President, Discovery at Gene Logic Inc. and had held senior and executive leadership positions in the biotechnology industry for seven years.